glp-1 drug mounjaro analogs, new trend in obesity treatment, become even more effective < Pharma < Article Mounjaro (Tirzepatide): Raising the Bar
Description
Effects of exenatide on measures of -cell function after 3 years in metformin-treated patients with type 2 diabetes

Our study detected a notable signal between different GLP-1 RAs and AP in the FAERS database throughout the study duration
However, the hormone proved disappointing in initial trials

Per the TrumpRx site, it is expected to launch in January 2026
The treatment is administered to reduce the risk of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes who were confirmed with cardiovascular disease
